Market revenue in 2023 | USD 450.0 million |
Market revenue in 2030 | USD 689.9 million |
Growth rate | 6.3% (CAGR from 2023 to 2030) |
Largest segment | Large molecules |
Fastest growing segment | Small molecules |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Large Molecules, Small molecules |
Key market players worldwide | Boehringer Ingelheim, Catalent Inc, Baxter International Inc, Eurofins Scientific SE, Recipharm, Fresenius SE & Co KGaA, Novartis AG ADR, Recro Pharma, Symbiosis Pharmaceutical Services, MabPlex International |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fill-finish pharmaceutical contract manufacturing market will help companies and investors design strategic landscapes.
Large molecules was the largest segment with a revenue share of 67.09% in 2023. Horizon Databook has segmented the UK fill-finish pharmaceutical contract manufacturing market based on large molecules, small molecules covering the revenue growth of each sub-segment from 2018 to 2030.
In the UK, fill-finish contract manufacturing is an important part of the pharmaceutical industry. The number of CMOs that specialize in fill-finish contract manufacturing is growing in the UK owing to the increasing demand in the market.
These companies generally have state-of-the-art facilities and equipment, as well as highly skilled personnel, to ensure that products are manufactured as per the highest quality standards. One of the key advantages of using a CMO for fill-finish contract manufacturing is that it allows pharmaceutical companies to outsource a critical part of the manufacturing process, which can be costly and time-consuming to perform in-house.
By partnering with a CMO, pharmaceutical companies can benefit from the CMO's expertise, experience, and specialized equipment, while also reducing its capital expenditure. Overall, the fill-finish contract manufacturing scenario in the UK is robust and competitive, with a number of high-quality CMOs offering a range of services to pharmaceutical companies.
Horizon Databook provides a detailed overview of country-level data and insights on the UK fill-finish pharmaceutical contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into UK fill-finish pharmaceutical contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account